Live Breaking News & Updates on Molecular diagnostics program
Stay updated with breaking news from Molecular diagnostics program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 26, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin®
(1) Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ -- Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company's Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled "Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization" was published in the American Journal of Physiology - Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and management of NAFLD/NASH disease. "Once validated in larger studies, non-invasive Liquid Biopsy diagnostic solutions such as the ones being developed by Molecular Stethoscope may be used serially not only as Drug Development Tools to monitor the ongoing challenging pharmacotherapy clinical trials, but also to follow cf-mRNA changes during lifestyle modification which has led to marked improvements in steatosis and fibrosis," commented Dr. Chalasani.
SEOUL, South Korea, Feb. 18, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics firm Seegene Inc. (KQ096530) reported preliminary financial results for the fourth quarter and the fiscal year of 2020, showing records never seen before. The company posted KRW 441.7 billion in consolidated revenue and KRW 257.5 billion in operating profit for th
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U.S. Department of Energy Isotope Program ?? -GEN isotope generator, which enables a nimble supply of therapeutic radioisotopes with the power of alpha-particle therapy for cancer CORALVILLE, IA / ACCESSWIRE / February 18, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into an agreement with the National Isotope Development Center (NIDC) for the long-term supply of parent feedstock radionuclide Th-228 for the manufacturing of the Company's Ra-224/Pb-212 generator, VMT-??-GEN. The long-term agreement provides deliveries from 2021 through 2030.
(MENAFN - The Conversation) Professor in Vaccinology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Profile Articles Activity Anna-Lise Williamson FRSSAf MASSAf is a Professor of Virology at the University of Cape Town. Williamson obtained her PhD from the University of the Witwatersrand in 1985. Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers MENAFN16022021000199003603ID1101611074 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
WASHINGTON (dpa-AFX) - Medical technology company Becton, Dickinson and Co. or BD (BDX)announced Friday that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization
socaltech.com San Diego-based virtual reality startup Nanome, which is developing technology to help researchers explore the interaction of molecules and molecular compounds using VR, has raised $3M in a funding round, the company disclosed today. The company said the funding was led by Bullpen Capital, as well as Formic Ventures, the venture capital investment firm of Oculus co-founder Michael Antonov. The company is led by CEO and founder Steve McCloskey, an alumni of the nanoengineering program at UC San Diego. Nanome's virtual reality tools allows researchers to interact with molecular structures using VR goggles and controllers.